Tuesday, October 10, 2023
Sunday, July 31, 2022
Pearls Chiari malformation
1.80 percent of patients with cough headache have cm type 1 although only a minority of patients with cm 1 have cough headache. The degree of tonsillar herniation does not correlate
2. Cm1 presents most often from ages 8 to 9 and from 31 to 46
3. Spinal cord syndrome occurs in 65 to 84 percent and includes weakness and sensory changes.
4. Brain stem syndrome occurs in 22 to 38 percent and includes blurred vision, horizontal or downbeating nystagmus, and diplopia (upper) or hoarseness , dysphonia, dysarthria, dysphasia, vocal cord paralysis, palatal weakness and tongue atrophy ( lower).
5. Cerebella symptoms occur in 11 percent with dyscoordination, ataxia and dysmetria
6. Cortical symptom is rare 3 percent with brain fog, depression, generalized weakness and fatigue
7. Even more rare systemic syndrome , two percent, have chest pain, sob, postural hypotension and syncope
8 presenting symptoms include 82 to 90 percent have suboccipital headache, 78 to 81 percent have posterior neck pain, 60 to 67 have dizziness, 49 percent have nausea.
Others with percent
Weakness. 69
Numbness 56
Altered temperature sensation 52
Unsteady 40
Double vision 13
Swallowing trouble 8
Tinnitus. 7
Dysarthria 3
Dizzy. 3
Hiccups. 1
9. Ciné mri phase contrast may show elevated high velocity jets upwards and other abnormalities of normal bidirectional csf flow. Technique also can be used to follow cm1. Technique is especially useful to differentiate headaches of cm1 v other causes
Sunday, November 22, 2020
Luna G, Alping P, Burman J et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximabm and injectable therapies. JAMA Neurology2020; 77:184-91.
Swedish study examines risk of infections severe enough to cause hospitalization in 6421 MS patients and controls. The rate of infections among patients taking injectibles was higher than the population 8.9 v 5.2 per 1000 person years. It was higher still in patients taking fingoli,od (14.3), and natalizumab (11.4) and highest among patients taking rituximab (19.7).
MG after dabrafenib and trametinib in metastatic melanoma. Case report. Neurology 2020; 94: 322-3/
In this patient, challenge , withdraw and rechallenge brought out MG symptoms and resolved when withdrawn within 24 hours. {atient was ab positive. These drugs, BRAF and MEK inhibitors now are standard of care for melanoma. This is a separate phenomenon from checkpoint inhibitors causing mg
Atrial fibrillation and falls: a mechanistic or age confounded relationship? (editorial) Mayo Clinic Proceedings 95; 2020, pp632-4 AuthorsHu T et al.
Meta-analysis shows falls and AF are related, independently of age. Odds ratio is about 1.8. The relationship exists even after pacemaker placement. Authors cite an AF complex of symptoms that include cognitive dysfunction, endothelial dysfunction and dysautonomia.
Wednesday, November 13, 2019
Dermatomyositis with and without anti Mi2 autoantibodies
Pinal-Hernandez I, Mecoli CA, Casal-Dominguez M . More prominent muscle involvement with dermatomyositis with anti Mi2 autoantibodies. Neurology; 2019; 93e1768-1777
(John Hopkins)
58 patients with antiMi2 positive DM
143 patient with anti Mi2 negative DM
162 patients with antisynthetase syndrome
170 patients with immune mediated necrotizing myopathy (IMNM).
Features of patients with antiMi2 positive DM: more muscle weakness, less calcinosis , less interstitial lung disease, higher CK level but still stronger with lower CK's than pats with IMNM
(John Hopkins)
58 patients with antiMi2 positive DM
143 patient with anti Mi2 negative DM
162 patients with antisynthetase syndrome
170 patients with immune mediated necrotizing myopathy (IMNM).
Features of patients with antiMi2 positive DM: more muscle weakness, less calcinosis , less interstitial lung disease, higher CK level but still stronger with lower CK's than pats with IMNM
Tuesday, February 07, 2017
Autoimmune meningoencephalitis associated with GFAP IgG antibodies.
Fung B et al. Autoimmune glial fibrillary acidic protein astrocytopathy: a novel meningoencephalomyelitis. JAMA Neurol 2016; 73: 1297.
Mayo labs has 134 cases out of 100,000 evaluated for autoimmune and paraneoplastic ab's as part of routine care. Clinical presentation consists of headache, confusion, behavioral changes, lethargy, blurred vision, and trouble walking. Exam can show papillitis, CN palsies, myelopathy. CSF can show pleocytosis, highprotein, OCB'sm high IgG index. MRI can show leptomeningeal enhancement, gyral enhancement. At least half relapsed despite corticosteroids. 6/16 developed cancers
Mayo labs has 134 cases out of 100,000 evaluated for autoimmune and paraneoplastic ab's as part of routine care. Clinical presentation consists of headache, confusion, behavioral changes, lethargy, blurred vision, and trouble walking. Exam can show papillitis, CN palsies, myelopathy. CSF can show pleocytosis, highprotein, OCB'sm high IgG index. MRI can show leptomeningeal enhancement, gyral enhancement. At least half relapsed despite corticosteroids. 6/16 developed cancers
Steroid sparing therapy in neurosarcoidosis
Neurology 2016; 13:87:2517 Uncontrolled study of 40 patients with neurosarcoidosis, both central and peripheral nerve. 32 got MTX 20 mg per week, 14 got mycophenolate (MMF) at 2 grams per day (median) 6 had both drugs successively. In MTX group, 15/32 (46 percent) relapsed v. 11/14 (79 %) in MMF group. Median survival without relapse was 28 months in MTX group, 11 month in MMF group. Of note steroid dose at initiation was 40 mg po daily in MTX group, and 20 mg in MMF group, a potential confound. Both groups had high rates of relapse and better steroid sparing drugs are needed.
Tuesday, November 29, 2016
Biotinidase deficiency mimicking NMO: initiallyexhibiting symptoms in adulthood
Bottin L, Prud'honS, Giannesini C et al. Multiple Sclerosis 21 (12) 1604-07 2015.
Authors present first case of biotinidase deficiency presenting in young adulthood ; children and adolescents may present with vision loss and tetraparesis. It was due in this case to a novel missense mutation and partly improved with oral biotin therapy.
Tuesday, November 08, 2016
Seropositive voltage gated calcium channels, utility
Jammoul A, Shayya L, Mente K
et al. Neurology Clinical Practice 2016; 6:409-418.
Authors differentiate "classic" group with limbic encephalitis or neuromyotonia (9.6% of total) and note the others had a panoply of diagnoses that were nonclassic. The classic group was more likely to have high titers of ab, but there was overlap. 91 % of lcassic and 21 % of nonclassic had levels > 0.25 nM. 75 % of patietns in high level ab group had autoimmune disorders, and 75 % of patients with low level titers did not. 26 % of patients had a remote malignancy (active, remote, solid or hematologic) but not ab titer difference was noted among the groups .
Conclusions: 1. High VGKC ab levels are found in patients with classic and other autoimmune disorderes, Low level ab titers are seen in nonspecific and mostly nonautoimmune disorders
2. The presence of VGKC antibodies rather than the level may serve as a marker of malignancy
Notes this is bad on a chart review of 6,032 patients who underwent evaluation .
The nonclassic group includes PNS and CNS diorders including neuropathy, dementia, ALS, CJD. Some patietns had nonspecific symptoms such as stutering speech, nausea and vomting and orthostasis without diagnosis of neurologic disease.
Cancers were oftendiagnosed due towhole body CT/PET; 2 patietns had previously unknown cancer (Ovarian and lung). Cancer occurred more commonly in those over age 45. Many cases of ab finding were remote by over ten years from actual tumor.
Authors differentiate "classic" group with limbic encephalitis or neuromyotonia (9.6% of total) and note the others had a panoply of diagnoses that were nonclassic. The classic group was more likely to have high titers of ab, but there was overlap. 91 % of lcassic and 21 % of nonclassic had levels > 0.25 nM. 75 % of patietns in high level ab group had autoimmune disorders, and 75 % of patients with low level titers did not. 26 % of patients had a remote malignancy (active, remote, solid or hematologic) but not ab titer difference was noted among the groups .
Conclusions: 1. High VGKC ab levels are found in patients with classic and other autoimmune disorderes, Low level ab titers are seen in nonspecific and mostly nonautoimmune disorders
2. The presence of VGKC antibodies rather than the level may serve as a marker of malignancy
Notes this is bad on a chart review of 6,032 patients who underwent evaluation .
The nonclassic group includes PNS and CNS diorders including neuropathy, dementia, ALS, CJD. Some patietns had nonspecific symptoms such as stutering speech, nausea and vomting and orthostasis without diagnosis of neurologic disease.
Cancers were oftendiagnosed due towhole body CT/PET; 2 patietns had previously unknown cancer (Ovarian and lung). Cancer occurred more commonly in those over age 45. Many cases of ab finding were remote by over ten years from actual tumor.
Pearls about GQ1b
Serum and CSF GQ1 ab'sin isolated opthalmoplegic syndromes. Spatola M, Du
Pasquier R, Schluep M, et al. Neurology 2016; 86:1780-1784
pearls about GQ1b from this article
1. Antibodies are specific for Miller Fisher syndrome (MFS); unl;ike
NMO-NMOSD, the use of the antibodies does not increase the spectrum of MFS
substantially
2. Measurement in CSF offers no additional value over serum
3. Although ON (optic neuritis) can occur as part of the MFS, ISOLATED ON
is NOT part of the MFS spectrum
4. In acute opthalmoplegia, only 1/21 had positive antibodies but the
antibodies occurred in 1/5 cases of AO of unknown etiology; therefore, the
antibody may be useful as part of the evaluation of AO. The cases with known
etiology include diabetes, Tolosa Hunt and opsoclonus myoclonus
5. Low serum titers occur in several disorders and are markers of
nonspecific damage to ocular motor nerve sheaths, while high concentrations are
specific for MFS
6. IgG is the most relevant isotype antibody relevant for MFS, and
GanglioCombi mixed IgM/IgG correlates well which makes it a viable alternative
Tuesday, September 27, 2016
Wednesday, June 01, 2016
Froin's syndrome
CSF showing high protein, xanthochromia and hypercoagulation of CSF is
pathognomonic and it can occur with blockage of CSF by a spinal cord mass or
meningeal irritation from meningitis.
Tuesday, February 23, 2016
Orthostatic tremor - pearls
Hassan A, Ahlskog AE, Matsumotos JY. Orthostatic tremor: clinical, electrophysiologic and treatment findings in 184 patients. Neurology 2016; 86: 458-464.
The article is a Mayo series of 184 patients seen over 37 years.
Definition: lower body tremor activated on standing, absent when seated or lying, improved by walking or leaning. Patients report leg shaking, unsteadiness and imbalance. Electrophysiologic findings are unique: a 13-18 hz tremor of lower limbs or trunk.
Demographics: 64 percent were female, mean age 59 years, (range 13-88) . One hundred percent reported symptoms only when standing and absent while seated. Descriptions included "imbalance, unsteadiness, weakness, 'funny feeling,' 'jelly legs,' leg tightness, pain, tremor, shakiness, or quivering. Sixty percent of cases included the arms. 24 percent had falls. 28 percent had other types of tremors included ET, which could be associated with a response to alcohol. Other associated tremors included head tremor (1), handwriting tremor (2), functional (1), jaw tremor (1). Forty percent had other neurologic diseases including Parkinson's and many others, degenerative or otherwise. Nine patients had a family history of orthostatic tremor.
Medication responsiveness occurred in 139 patients. Sixty seven percent of medications prescribed did not demonstrate benefit. The most efficacious was benzodiazepines, especially clonazepam, with 48 percent of patients so treated showing moderate or marked benefit. Thirty three percent of patients given gabapentin showed mild or moderate benefit, with lower responses to valproate, primidone, levodopa (only 1/33 responding), and no benefit from anxiolytics or antidepressants. The responsiveness to clonazepam diminished over time , and of those only a few, 16 got benefit from another drug, including gabapentin, valproic acid, propranolol, pramipexole, bromazepam, primidone, carbi-levodopa, and pregabalin. Three patients underwent DBS and improved.
There was a high personal anf family history of PD (8.9 and 10.7 percent).
EMG is easy and pathognomonic. MRI's often show various types of white matter disease and occasional meningiomas.
The article is a Mayo series of 184 patients seen over 37 years.
Definition: lower body tremor activated on standing, absent when seated or lying, improved by walking or leaning. Patients report leg shaking, unsteadiness and imbalance. Electrophysiologic findings are unique: a 13-18 hz tremor of lower limbs or trunk.
Demographics: 64 percent were female, mean age 59 years, (range 13-88) . One hundred percent reported symptoms only when standing and absent while seated. Descriptions included "imbalance, unsteadiness, weakness, 'funny feeling,' 'jelly legs,' leg tightness, pain, tremor, shakiness, or quivering. Sixty percent of cases included the arms. 24 percent had falls. 28 percent had other types of tremors included ET, which could be associated with a response to alcohol. Other associated tremors included head tremor (1), handwriting tremor (2), functional (1), jaw tremor (1). Forty percent had other neurologic diseases including Parkinson's and many others, degenerative or otherwise. Nine patients had a family history of orthostatic tremor.
Medication responsiveness occurred in 139 patients. Sixty seven percent of medications prescribed did not demonstrate benefit. The most efficacious was benzodiazepines, especially clonazepam, with 48 percent of patients so treated showing moderate or marked benefit. Thirty three percent of patients given gabapentin showed mild or moderate benefit, with lower responses to valproate, primidone, levodopa (only 1/33 responding), and no benefit from anxiolytics or antidepressants. The responsiveness to clonazepam diminished over time , and of those only a few, 16 got benefit from another drug, including gabapentin, valproic acid, propranolol, pramipexole, bromazepam, primidone, carbi-levodopa, and pregabalin. Three patients underwent DBS and improved.
There was a high personal anf family history of PD (8.9 and 10.7 percent).
EMG is easy and pathognomonic. MRI's often show various types of white matter disease and occasional meningiomas.
Sunday, January 03, 2016
Pellagra and spinal myoclonus
Park K, Oeda T, Sawada H. A case of alcoholic pellegra encephalopathy
presenting with spinal myoclonus. Neurology Clinical Practice 5; 472-3.
The authors present a case of alcoholic pellagra with confusion and
myoclonus responding dramatically to administration of niacin1500 mg per day
starting 16 days after admission. Essential points include:
1. Pellagra is rare in US but not in alcoholics
2. Dermatitis may be subtle and not appreciated
3. Thiamine and niacin levels may be normal
4. Thiamine may cause worsening due to increased demand for niacin
5. Myoclonus in context is important to diagnosis, often stimulus
sensitive
6. Severe sensory ataxia, incontinence and dysautonomia also occur and
improve with treatment
the 4 D's of pellagra, again, are , diarrhea, dementia, dermatitis and
death
Additional pearl-- hamsters exposed to niacin deficiency (corn maize diet) cannibalize their young-- cite Current Nature ?
Additional pearl-- hamsters exposed to niacin deficiency (corn maize diet) cannibalize their young-- cite Current Nature ?
Scurvy and Neurologic disease
Meisal K, Daggubati S,Josephson SA. . Scurvy in the 21st century? Vitamin
C deficiency presenting to the neurologist. Neurol Clin Prac 2015;
5:491-493.
Authors present a series of cases with vitamin C deficiency and review some
of the neuro manifestations and non neuro manifestations, ; the former are not
widely known.
Patients with deficiency were caused by various other causes,including
autism, poor status without access to produce, usually rural, were not alcohol
users, had measurable low vitamin C levels. Gingival hyperplasia, rash and
bleeding were non neurologic manifestations. People bruised,especially on their
thighs, Some had other nutritional diseases.. Pain, achiness and weight loss
are expected.
Neuro manifestations included positional tremor, neuralgias100 %), focal
weakness (50 %) including footdrop and scapular winging, normal MRI's, long
tract signs including hyperreflexia and plantar extensors, fatigue, trouble
concentrating, headache, anxiety, and imbalance.
Patients recovered dramatically with treatment.
Malignant subtypes of Parkinsons
JAMA Neurology august 2015
Importance There is increasing evidence that Parkinson disease (PD) is heterogeneous in its clinical presentation and prognosis. Defining subtypes of PD is needed to better understand underlying mechanisms, predict disease course, and eventually design more efficient personalized management strategies.
Objectives To identify clinical subtypes of PD, compare the prognosis and progression rate between PD phenotypes, and compare the ability to predict prognosis in our subtypes and those from previously published clustering solutions.
Design, Setting, and Participants Prospective cohort study. The cohorts were from 2 movement disorders clinics in Montreal, Quebec, Canada (patients were enrolled during the period from 2005 to 2013). A total of 113 patients with idiopathic PD were enrolled. A comprehensive spectrum of motor and nonmotor features (motor severity, motor complications, motor subtypes, quantitative motor tests, autonomic and psychiatric manifestations, olfaction, color vision, sleep parameters, and neurocognitive testing) were assessed at baseline. After a mean follow-up time of 4.5 years, 76 patients were reassessed. In addition to reanalysis of baseline variables, a global composite outcome was created by merging standardized scores for motor symptoms, motor signs, cognitive function, and other nonmotor manifestations.
Main Outcomes and Measures Changes in the quintiles of the global composite outcome and its components were compared between different subtypes.
Results The best cluster solution found was based on orthostatic hypotension, mild cognitive impairment, rapid eye movement sleep behavior disorder (RBD), depression, anxiety, and Unified Parkinson’s Disease Rating Scale Part II and Part III scores at baseline. Three subtypes were defined as mainly motor/slow progression, diffuse/malignant, and intermediate. Despite similar age and disease duration, patients with the diffuse/malignant phenotype were more likely to have mild cognitive impairment, orthostatic hypotension, and RBD at baseline, and at prospective follow-up, they showed a more rapid progression in cognition (odds ratio [OR], 8.7 [95% CI, 4.0-18.7]; P < .001), other nonmotor symptoms (OR, 10.0 [95% CI, 4.3-23.2]; P < .001), motor signs (OR, 4.1 [95% CI, 1.8-9.1]; P = .001), motor symptoms (OR, 2.9 [95% CI, 1.3-6.2]; P < .01), and the global composite outcome (OR, 8.0 [95% CI, 3.7-17.7]; P < .001).
Conclusions and Relevance It is recommended to screen patients with PD for mild cognitive impairment, orthostatic hypotension, and RBD even at baseline visits. These nonmotor features identify a diffuse/malignant subgroup of patients with PD for whom the most rapid progression rate could be expected.
Importance There is increasing evidence that Parkinson disease (PD) is heterogeneous in its clinical presentation and prognosis. Defining subtypes of PD is needed to better understand underlying mechanisms, predict disease course, and eventually design more efficient personalized management strategies.
Objectives To identify clinical subtypes of PD, compare the prognosis and progression rate between PD phenotypes, and compare the ability to predict prognosis in our subtypes and those from previously published clustering solutions.
Design, Setting, and Participants Prospective cohort study. The cohorts were from 2 movement disorders clinics in Montreal, Quebec, Canada (patients were enrolled during the period from 2005 to 2013). A total of 113 patients with idiopathic PD were enrolled. A comprehensive spectrum of motor and nonmotor features (motor severity, motor complications, motor subtypes, quantitative motor tests, autonomic and psychiatric manifestations, olfaction, color vision, sleep parameters, and neurocognitive testing) were assessed at baseline. After a mean follow-up time of 4.5 years, 76 patients were reassessed. In addition to reanalysis of baseline variables, a global composite outcome was created by merging standardized scores for motor symptoms, motor signs, cognitive function, and other nonmotor manifestations.
Main Outcomes and Measures Changes in the quintiles of the global composite outcome and its components were compared between different subtypes.
Results The best cluster solution found was based on orthostatic hypotension, mild cognitive impairment, rapid eye movement sleep behavior disorder (RBD), depression, anxiety, and Unified Parkinson’s Disease Rating Scale Part II and Part III scores at baseline. Three subtypes were defined as mainly motor/slow progression, diffuse/malignant, and intermediate. Despite similar age and disease duration, patients with the diffuse/malignant phenotype were more likely to have mild cognitive impairment, orthostatic hypotension, and RBD at baseline, and at prospective follow-up, they showed a more rapid progression in cognition (odds ratio [OR], 8.7 [95% CI, 4.0-18.7]; P < .001), other nonmotor symptoms (OR, 10.0 [95% CI, 4.3-23.2]; P < .001), motor signs (OR, 4.1 [95% CI, 1.8-9.1]; P = .001), motor symptoms (OR, 2.9 [95% CI, 1.3-6.2]; P < .01), and the global composite outcome (OR, 8.0 [95% CI, 3.7-17.7]; P < .001).
Conclusions and Relevance It is recommended to screen patients with PD for mild cognitive impairment, orthostatic hypotension, and RBD even at baseline visits. These nonmotor features identify a diffuse/malignant subgroup of patients with PD for whom the most rapid progression rate could be expected.
Friday, August 21, 2015
Drug choices for juvenile myoclonic epilepsy
valproic acid
topiramate
lamotrigine
levetiracetam
zonisamide
note these are the "broad spectrum drugs"
also note: valproic acid and topiramate are teratogenic
topiramate
lamotrigine
levetiracetam
zonisamide
note these are the "broad spectrum drugs"
also note: valproic acid and topiramate are teratogenic
AED's and psychiatric function
Psychiatric function worse:
levetiracetam
topiramate
zonisamide
tiagabine
phenobarbital
periampanel
psychiatric function better
carbamazepine
valproic acid
lamotrigine
pregabalin
levetiracetam
topiramate
zonisamide
tiagabine
phenobarbital
periampanel
psychiatric function better
carbamazepine
valproic acid
lamotrigine
pregabalin
Subscribe to:
Posts (Atom)